



Rayaldee® Access and affordability.

Commercial insurance: Rayaldee® is covered by payers representing nearly 80% of the U.S. commercially insured patients.[†]
Eligible commercially insured patients pay \$0.¹

TRICARE:

\$76 copay for up to a 90-day supply via TRICARE® Pharmacy Home Delivery.²
\$76 copay for up to a 30-day supply via TRICARE® retail network pharmacy.²

Medicaid: Rayaldee® is covered by payers representing nearly 100% of the U.S. Medicaid insured population.[†] Coverage requirements vary by payer.
Eligible Medicaid patients pay \$0 - \$5 per fill.³

Medicare Part D:

Medicare Part D enrollees will pay \$0 for their covered prescription drugs for the rest of the calendar year after reaching their \$2,000 out-of-pocket cap.⁵

Low Income Subsidy:

(LIS, Dually Eligible, Medi-Medi, Extra Help)

Eligible LIS patient out-of-pocket cost is \$0 - \$12.15 per fill.⁴
(not subject to the \$2,000 out-of-pocket cap)

OPKO CONNECT

RAYALDEE® PATIENT ASSISTANCE PROGRAM (PAP)

OPKO Connect has a Rayaldee® Patient Assistance Program (PAP) that offers free medication for patients without pharmacy insurance coverage or unable to afford their Rayaldee® copay. Eligibility criteria apply and annual re-enrollment is required.^{††}

REAL SUPPORT FOR YOUR PATIENTS



1. Eligible commercially insured patients can fill their Rayaldee prescription for \$0 with eVoucherRx™, a program from RelayHealth that automatically applies copay savings at patient's pharmacy. If the patient's pharmacy does not work with RelayHealth eVoucherRx™, then OPKO Connect has a \$0 copay program for eligible commercial insured patients.
2. TRICARE® Cost and Fees 2025 Preview: https://tricare.mil/-/media/Files/TRICARE/Publications/FactSheets/CostsFees_FS_2025_Preview_508c_FINAL_110824.pdf. Date accessed: February, 2025.
3. Each state Medicaid program is different and will determine the out-of-pocket cost.
4. OPKO Connect and Specialty Pharmacy case data, February, 2025.
5. CMS.gov Part D Improvements: <https://www.cms.gov/inflation-reduction-act-and-medicare/part-d-improvements>. Date accessed: February, 2025.

[†] Managed Markets Insight & Technology as of February, 2025.

^{††} Patient must be prescribed RAYALDEE for on-label usage and patient combined household income must be no more than 200% of the Federal Poverty Level (FPL).

What is OPKO CONNECT?

OPKO Connect is a patient reimbursement hub offering support for your office on behalf of your patients who have been prescribed **Rayaldee®**.

Services include:


- Benefits investigation
- Prior Authorization (PA) or Formulary Exception support
- Support for appeals if the PA or Formulary Exception is denied
- Copay assistance
- Patient Assistance Program (PAP)
- Contact with patients to help maintain adherence to therapy

Contact **OPKO Connect** to help your patients receive Rayaldee®.

Phone: 1-844-414-OPKO (6756)

Email: opkoconnect@rxallcare.com

Hours: Monday through Friday, 8 am to 8 pm ET



Get started. Prescribe Rayaldee® (calcifediol) today!

SCAN TO LEARN MORE

Option 1: via **OPKO Connect** by sending a Service Request Form (SRF)

Option 2: via your preferred specialty pharmacy by sending a prescription

Visit www.rayaldee.com/hcp-financial-support/ to download the **Service Request Form** and to find additional information about **OPKO Connect** support.



INDICATION AND LIMITATIONS OF USE:

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee® is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

IMPORTANT SAFETY INFORMATION:

• **Hypercalcemia:** excessive administration of vitamin D compounds, including Rayaldee®, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium. • **Digitalis toxicity:** potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee®. • **Adynamic bone disease:** monitor for abnormally low levels of parathyroid hormone (PTH) levels when using Rayaldee® and adjust dose if needed. • The most common adverse reactions ($\geq 3\%$ and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. • Care should be taken while dosing Rayaldee® with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions. • Serum calcium should be below 9.8 mg/dL before initiating treatment. • Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and parathyroid hormone (PTH) 3 months after starting therapy or changing dose.

Please see **Important Safety Information and Full Prescribing Information** available at www.rayaldee.com.

RAYALDEE® is a registered trademark of Eirgen Pharma Ltd. OPKO Renal is a division of OPKO Health, Inc. © 2025 OPKO Pharmaceuticals, LLC. All rights reserved. OP-US-0579-012025v.6